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Molecular mimicry is fundamental to biology and transcends to many disciplines ranging
from immune pathology to drug design. Structural characterization of molecular partners
has provided insight into the origins and relative importance of complementarity in mimicry.
Chemical complementarity is easy to understand; amino acid sequence similarity between
peptides, for example, can lead to cross-reactivity triggering similar reactivity from their
cognate receptors. However, conformational complementarity is difficult to decipher. Mol-
ecular mimicry of carbohydrates by peptides is often considered one of those. Extensive
studies of innate and adaptive immune responses suggests the existence of carbohy-
drate mimicry, but the structural basis for this mimicry yields confounding details; peptides
mimicking carbohydrates in some cases fail to exhibit both chemical and conformational
mimicry. Deconvolution of these two types of complementarity in mimicry and its relation-
ship to biological function can nevertheless lead to new therapeutics. Here, we discuss our
experience examining the immunological aspects and implications of carbohydrate–peptide
mimicry. Emphasis is placed on the rationale, the lessons learned from the methodologies
to identify mimics, a perspective on the limitations of structural analysis, the biological
consequences of mimicking tumor-associated carbohydrate antigens, and the notion of
reverse engineering to develop carbohydrate-mimetic peptides in vaccine design strategies
to induce responses to glycan antigens expressed on cancer cells.
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INTRODUCTION
Among the most challenging of antigen targets for vaccine design
are glycans (1). They are ubiquitous in nature and can be con-
sidered as one of the unique antigens expressed across pathogens
and cancer cells. Glycans are fundamental to the biological func-
tions of cell–cell communication, cell proliferation, and differen-
tiation, and they mediate cell attachment, as well as mediating
pathogen attachment and infection. Cancer cells, in particular,
are noted for their aberrant glycosylation profiles that affect the
metastatic process. Consequently, certain carbohydrate forms pro-
foundly affect both the pathophysiology of infection and neoplasia
(Table 1). A unique advantage in targeting tumor-associated car-
bohydrate antigens (TACAs) is that multiple proteins and lipids on
cancer cells can be modified with the same carbohydrate structure
which might be shared with bacterial antigens (2). Thus, target-
ing TACAs has the potential to broaden the spectrum of antigens
recognized by the immune response, thereby lowering the risk
of developing resistant tumors due to the loss of a given protein
antigen.
We have come to learn that the manner a TACA is expressed
will dictate how an immune effector mechanism will be invoked
(8). Antibodies against glycolipids and globular glycoproteins are
found to mediate complement-dependent cytotoxicity (CDC)
because they extend less than 100 angstroms from the cell
membrane while antibodies to mucins that extend up to 5000
angstroms from the cell surface do not (8). But TACAs are also
associated with cell signaling activities whereby anti-TACA anti-
bodies are capable of direct induction of cell death of number of
tumor cell lines, but this activity has not been investigated in great
detail (9, 10). In this context, TACAs are pan-targets on tumor cells
because they are collectively and intimately involved in cell-death
signaling pathways. Strategies that target TACAs have, therefore,
potential clinical benefit as cell-death therapies. Anti-TACA anti-
bodies can mediate significant reprograming of signaling events,
with profound anti-tumor activities. The ability to induce anti-
bodies reactive with multiple TACAs is relevant as heterogeneity
of antigen expression in different cancers of the same type, as well
as different cells of the same cancer, and heterogeneity of immune
response in different patients make it likely that maximal anti-
cancer effect may not result from immunization against a single
antigen.
The success of carbohydrate-based vaccines against pathogens
has led to technological advances in vaccine design, but they have
typically been developed as mono or singular vaccine types requir-
ing a polyvalent formulation to induce responses across carbohy-
drate types (11). While glycans are diverse in expression patterns
and in their composition, the structural commonalities among gly-
cans provide a template to target, at least some of them collectively,
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Table 1 | Glycosphingolipid Constituents Shared Among Bacteria and
Tumor cells.
GSL series type Structure Bacterial species
Lacto Galβ1→4GlcNAcβ1→
3Galβ1→4Glcβ1→Cer
N. gonorrhoeae
N. meningitidis
Moraxella catarrhalis
Helicobacter pylori
H. influenzae
Campylobacter jejuni
H. ducreyi
Globo Galα1→4Galβ1→4Glcβ1
→Cer
N. gonorrhoeae
N. meningitidis
H. influenzae type b
H. influenzae NT
B. catarrhalis
Ganglio GalNAcβ1→4Galβ1→4Glcβ1
→Cer
N. gonorrhoeae
Galβ1→3GalNAcβ1→4Galβ1
→4Glcβ1
GalNAcβ1→3Galβ1→
4GlcNAcβ1→3Galβ1→4Glcβ1
→Cer
Lacto series, neolactoseries, Globosides, and Ganglioside antigens are found on
tumor cells (3, 4) and on LOS of multiple bacteria (5–7).
by directing the immune response toward these commonalities.
Therefore, it is logical to target glycans in vaccine design, which
can lead to the interruption of disease processes (11).
Among potential technological strategies is using carbohydrate-
mimetic peptides (CMP) to induce responses to glycans on
pathogens and cancer cells (12). Peptides can substitute as
immunogens to target pathways involving protein–carbohydrate
interactions and in carbohydrate-specific immunological reac-
tions. However, there is a noted distinction between the ideas
of antigenic mimicry versus the ability of a mimic to induce a
response cross-reactive with a carbohydrate/glycan moiety.
Antigenic mimicry, in simple terms, is when one ligand com-
petes with another for antibody binding. The origin of cross-
reactivity involves thermodynamic and structural interpretations
(13–15). The notion of immunological mimicry is less precise.
Does it mean that the mimic generates the same antibody sub-
set as the nominal antigen or just that it induces a response that
cross-reacts with the nominal antigen?
Early on CMPs were shown to function as antigenic mim-
ics (16, 17) but more importantly they were shown to induce
serum antibodies in a variety of systems, having utility in directing
responses to cancer cells and against pathogens (18–26). Most of
all, unlike carbohydrate antigens, CMPs can prime for memory
responses to TACAs (27) suggesting that the CMPs facilitate cog-
nate interactions between B cells and T cells, which is something
that carbohydrates/polysaccharides do not facilitate, but surro-
gate antigens of carbohydrates such as anti-idiotypic antibodies
and CMPs should and can do. CMPs are not only a functional
strategy to induce carbohydrate-reactive responses, but also they
can function as probes to understand the structural basis for the
dual recognition properties of antibodies, lectins, and T cells (12,
14, 15, 28, 29). Understanding the structural requirements for
antibody and T-cell recognition provides a basis for identifying
potentially new sets of immunogens that may have both funda-
mental immunological and clinical value. However, it has been
argued that translation of such information into viable vaccines
is still a long way off (30–32). Here, we briefly discuss the various
perspectives and elements of CMPs useful to translate them into
the clinic in tumor vaccine design applications to target glycans.
MOLECULAR MIMICRY AT A GLANCE
Molecular mimicry is now firmly considered as the basis of many
autoimmune disorders, proposed as a pathogenic mechanism for
autoimmune disease, as well as a probe useful in uncovering its
etiologic agents (33). On the other hand, self-limiting autoim-
munity may underlie some of the pathogenic mechanisms in
infectious disease. This hypothesis is based in part on observed
cross-reactivity of immune reagents with host “self” antigens and
microbial determinants (33). Molecular mimicry is also suggested
as a means to regulate immune homeostasis and to elicit responses
against target antigens as evidenced by studies on anti-idiotypic
antibodies (34). This model suggests that conventional T-cell/B-
cell collaboration can explain communication between comple-
mentary idiotype [Id(+)] and anti-Id antibody at the cellular level
that integrates present and previous data on B-cell regulation.
Furthermore, this model provides a tool to probe carbohydrate
immunology paradigms because the synergistic interaction of
effector T and B cells require common recognition of identical
tumor-associated antigen(s) (35). Anti-idiotypic antibodies have
been proposed to mimic carbohydrate antigens and have been
tested in the clinic (36–40).
At one level, an explanation for molecular mimicry is when
a foreign antigen shares sequence or structural similarities with
self-antigens. But on another level what defines the recognition
and interaction basis for antigenic mimicry that ties to a functional
immune response? Molecular mimicry in the context of antibody–
antigen recognition is interpreted at several levels (Figure 1). The
work by Hoffmuler et al. (41) suggests that a common epitope
can be preserved among an ensemble of peptide variants. They
demonstrated that the binding modes of intermediate conforma-
tion of selected peptides were characterized using complete sets
of substitution analogs, revealing that a number of sequential
substitutions accumulated without changing the pattern of key
interacting residues. At a distinct step, however, one single amino
acid exchange induces a change in the binding mode, indicating
a flip in specificity and conformation (41). Regions of proteins
with biased amino acid composition [so-called Low-Complexity
Regions (LCRs)] are abundant in the protein universe (42). LCR-
containing proteins tend to have more binding partners across
different networks than proteins that have no LCRs. LCRs may
be involved in flexible binding associated with specific functions,
but also that their positions within a sequence may be important
in determining both their binding properties and their biological
roles (42).
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FIGURE 1 | Illustrative models highlighting the polyspecificity or cross
reactivity of antigens for an antibody. (A) Two different molecules may
carry the same structure. (B) The same paratope may accommodate
multiple smaller epitopes in different parts. (C) The flexibility of the paratope
may allow for interaction with different epitopes. (D) Different flexible
molecules with repetitive low complexity structure containing common
groups (e.g., sugars) have a high probability of fitting in the same paratope.
These are aspects of polyspecific binding, which are partially related (like A
and D) and sometimes may occur in combination (C and any one of
the rest).
Intrinsically disordered regions of proteins have also been asso-
ciated with molecular mimicry (43), indicating the potential of
highly flexible peptides as mimics. Such peptides may be attrac-
tive to induce pan anti-tumor responses, due to their potential
ability to mimic multiple TACAs in situ. However, the structural
diversity inherent to such peptides makes defining the precise
nature of their mimicry of any or multiple TACAs even more chal-
lenging. Geometrical shape complementarity, the “lock and key”
hypothesis, between antigen–antibody interaction, has long dom-
inated immunological thinking. However, studies demonstrating
the existence of a large number of monoclonal antibodies that can
bind to a variety of totally unrelated self and foreign antigens (i.e.,
polyreactive antibodies) have modified this view. Consequently
the lock and key model has been supplemented with an explana-
tion focusing on the flexibility of antibody binding sites that can
change conformation to accommodate different antigens (44).
Antibodies induced by a CMP to the meningococcal group C
capsular polysaccharide (18) were shown to be reactive with the
Lewis Y antigen (20). Carbohydrate-reactive antibodies show the
potential cross-reactivity for dissimilar carbohydrate forms that
highlight the common epitope basis for cross-reactivity (Figure 2);
Figure 2A shows that a common epitope is formed between α2–8
sialic acid and the neolactoseries antigen Lewis Y (18, 20). The
potential of antibodies recognizing three hydroxyl groups might
be cross-reactive with three hydroxyl groups displayed on two gly-
cosyl groups (Figure 2B). This level of recognition leads to the
idea that antibodies can recognize carbohydrate in the context of
pan-recognition. The cases discussed above relate as much to the
common epitope mechanism as to the low-complexity epitopes,
which seems to be often the case in carbohydrate recognition.
What is discussed here, strictly speaking, is molecular interac-
tion at the atomic level, while recognition is rather the system
level processing of information relevant to immune function,
i.e., self/non-self distinction and identification of previously met
danger (32, 45). Specificity of interaction serves these purposes
only in some aspects while others favor polyspecific binding. For
T-cell receptors (TCR) antigen specificity is an emerging prop-
erty of the system rather than a characteristic of the individual
receptor (46). On a molecular level, TCRs are a rather promis-
cuous binder. Furthermore, in terms of pre-immune antibodies,
polyspecificity has also the role of ensuring a complete reper-
toire. It funnels antigen/pre-immune antibody interactions into
the somatic hypermutation process of refining specificity.
An interesting twist to this topic is the emerging notion of
reverting specific antibodies to polyspecific binding or induced
polyspecificity as a physiological mechanism operating for
instance at the sites of inflammation (47–49). Yet, perhaps to most,
typical polyspecific immune binding makes use of pattern recog-
nition to generalize a danger context (50, 51). Functionally, the
boundary between pattern recognition receptors and natural anti-
bodies is fuzzy (52–54). Intrinsically, prone to polyspecificity by
several mechanisms, antibody recognition of carbohydrates con-
ceptually merges antigen and pattern recognition. In this regard,
carbohydrate mimotopes (e.g., CMP) instead of mimicking one
particular structure by another come about rather as mimics of
patterns, not unlike synthetic TLR agonists. But carbohydrate
mimotopes are not exclusively artificial. CMPs from natural pro-
teins are known for some time (55, 56). Peptides from Mucin 1
cell surface receptor (MUC1) are the most interesting because they
are considered mimics of the Gal-epitope (56). Natural peptides
can adopt structures similar to carbohydrate antigens (21) and can
exhibit binding kinetics similar to the nominal antigens that they
mimic (21, 28).
Often times CMPs share no obvious consensus sequence but
their amino acid sequences often contain aromatic and hydropho-
bic residues but also amino acids having cyclic side chains, includ-
ing proline and glycine that affects the conformational properties
of the mimic (13, 57). The predominance of aromatic residues
in CMPs invokes interaction scenarios that include stacking and
hydrophobic interactions. A basis for this is the notion that car-
bohydrate recognition by antibodies use hydrophobic faces on
carbohydrate antigens (58). It is important to note that cohesive
solvent–solvent interactions are the major driving force behind
apolar association in solution (59). Consequently, interaction
models that implicate important roles for dispersion forces in mol-
ecular recognition events should be interpreted with caution in
solvent-accessible systems (59). In addition, other antibody recog-
nition systems also suggest that dual antigen recognition could
involve divergent antibody conformations of nearly equivalent
energetic states (60). Therefore, developing high-affinity-binders
might make use of antibody structural plasticity to mediate the
recognition step without increasing the entropic cost (60).
HUMORAL RESPONSES TO CMPs
While a variety of CMPs have been developed with the ability to
induce immune responses of desired specificities and functionality
(61) they are perhaps most appealing as a probe to understand the
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FIGURE 2 | Examples depicting similarity of epitopes in dissimilar
carbohydrate antigens. Epitopes (hydroxyls) are represented by red-spheres.
(A) Relationship between Lewis Y antigen on left side of panel with MCP on
right side. (B) Relationship between Lewis Y antigen on left side of panel with
α1–4 Glucose on right side of panel. Interestingly the epitope defined on the
glucose moiety defines a three-dimensional epitope on the Lewis Y antigen.
immunological response to carbohydrate antigens. An important
feature of CMPs is in their ability to mediate contact-dependent
T-cell help as an obligatory role in humoral immune responses
to T-cell dependent antigens. Cognate B-cell/T-cell interactions
during the immune response to protein antigens depend on T-cell
co-stimulation. Details of how such interactions govern immune
responses to carbohydrate-conjugate vaccines are few. We have
shown that immunization with CMPs activate peptide-specific T
helper type 1 (Th1) and type 2 (Th2) responses (62, 63). How-
ever, while behaving like a Th1 antigen (63), multivalent peptide
mimetics still could induce a high carbohydrate-reactive IgM/IgG
ratio with an endpoint titer of 1:2,000 (20). These results sug-
gest that the multiple antigen peptide form might function like
a Th2 independent immunogen in BALB/c mice. Furthermore,
we observed that CMPs mediate cognate B and T-cell interac-
tions as CMPs can induce antibodies in a host with deficiency
in IgM production that typically do not respond to carbohydrate
antigens (62). In these studies apparently the B cells functioned as
antigen-presenting cells. In addition, these studies suggest that B-
cell subsets influence the interactions. More importantly, the type
of TACA mimicked by the CMPs is expressed in mice (29, 64).
Consequently, these studies are obtained in a toleragenic mouse
model, further suggesting that tolerance is broken upon CMP
immunization.
A characteristic of an effective mimotope based vaccine would
be to prime for secondary responses upon boosting or challenge
with native antigen (18,27,65–67). Peptide-mimotope anamnestic
responses have been noted for mimotope-conjugates (65, 66). The
identification of peptide mimetics relies upon the idea that anti-
body fine specificity epitope mapping patterns of carbohydrates
and peptide mimetics might be used as a proxy for individual
B-cell receptor specificity activated during a secondary antibody
response. However, the idea of functional mimicry would suggest
that immunization with a carbohydrate-mimic peptide might also
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induce a specific subset or restricted anti-carbohydrate response.
Our studies indicate that since peptide-conjugates elicit immune
responses in xid mice (62), it is likely that antibodies to peptide
and carbohydrate immunogens might be structurally unique and
derived from different antibody subsets.
POTENTIAL FOR CELLULAR IMMUNITY TARGETING CARBOHYDRATE
ANTIGENS
Up until a few years ago, carbohydrate determinants were tradi-
tionally not considered as targets for Cytotoxic T-Lymphocytes
(CTL) despite a variety of immunogenicity and specificity studies
for the glycan moiety of synthetic O-glycosylated MHC-binding
peptides suggest otherwise (68–70). GD2 was also implicated as a
target upon CTL activation early on (71). Crystal structure analy-
ses indeed show that T cells can recognize glycopeptides bound by
MHC molecules on the surface of antigen-presenting cells (72, 73).
T cells, therefore, have the potential to react with the carbohydrate
moiety of neoglycopeptide antigens, suggesting that T cells can tar-
get carbohydrate antigens expressed on tumor cells. However, it is
also possible to generate carbohydrate-specific unrestricted CTL
responses with MHC class-I-binding carrier peptides (74) that
might explain the GD2 response (71). Nonetheless,how such T-cell
responses are generated is presently unclear. From a vaccine per-
spective, the construction of glycopeptide/protein immunogens is
problematic.
Rather than simple molecular mimicry, unpredictable arrays
of common and differential contacts on class-I complexes can be
used for their recognition by the same TCR. For example, bacte-
rial polysaccharides with a distinct charge-motif can be emulated
by peptides that can activate T cells (75). Lysine–aspartic acid
(KD) peptides with repeating units are able to stimulate CD4+
T cells in vitro and confer protection against abscesses induced
by bacteria such as Bacteroides fragilis and Staphylococcus aureus
(75). CMPs can induce a Th1 response in mice using a DNA
platform (76). We have observed an augmented induction of
CTL activity against Meth A tumor cells upon peptide-mimotope
immunization (63, 77). The induction of carbohydrate-reactive
T-lymphocytes with peptide mimics is based upon a functional
definition of T-cell mimotopes. One possible explanation is that
the peptide-mimotope activates CTLs, which bind to O-linked
GlcNAc or GalNac glycopeptides associated with MHC Class-I.
Based upon crystal structure analysis of MHC complexes with
glycopeptides, it appears that the central region of the putative
T-cell-receptor-binding site is dominated by the extensive expo-
sure of the tethered carbohydrate (72, 73). Our modeling of CMPs
in the MHC Class-I groove suggests that amino acids and glycans
attached to a glycopeptides overlap in 3D space, providing an array
of contacts for TCR recognition (12).
FIDELITY IN MIMICRY
The ability to augment or enhance TACA-reactive antibodies using
CMPs would be noteworthy. Much like anti-idiotypes, CMPs may
elicit anti-saccharide responses, but fail to elicit the idiotypes and
isotypes observed in the protective response to the microbial anti-
gen (78). Functional antibodies depend not only on the host’s
ability to mount an immune response, but also on its ability to
mount the appropriate immune response. Whether an antibody
response is protective or not may depend on both the fine anti-
genic specificity that may be associated with particular idiotypes
and epitope binding characteristics, and the isotype, determining
antibody effector function. Often times studies of peptide mimics
selected by lectins or antibodies and then analyzed by structural
approaches come to the conclusion that mimicry at structural level
is minimal at best (13–15). The same conclusions are drawn in con-
sidering anti-idiotypic antibodies (79). Rather, mimics as peptides
or anti-idiotypes serve as imprints of the structural characteristics
of the nominal carbohydrate antigen and, consequently, give rise to
antibodies with carbohydrate-like properties upon immunization.
The question remains how to enhance the ability of TACA-mimetic
peptides to induce TACA-reactive antibodies with higher titers
and association constants. Herein lies the problem with mimics;
the immune response is only assayed after a choice is made as to
which mimic is to be followed. So what lessons can be learned
about choosing the “true” mimic?
From lectins to vaccines
While lectins have been generally used to identify CMPs and
to understand the general features of recognition phenomena,
Figure 3 outlines the general development of CMPs in vaccine
design using lectins as a template to induce antibodies that would
emulate the actions of lectins. We have shown that this concept
can be brought into practice (80). Plant lectins like Griffonia
simplicifolia lectin I (GS-1) and wheat germ agglutinin (WGA)
mediate the apoptosis of tumor cells. We have investigated the
possibility of using these lectins as templates to select peptide-
mimotopes of TACAs as immunogens to generate cross-reactive
antibodies capable of mediating apoptosis of tumor cells (80).
FIGURE 3 | General scheme of translating process of random phage
library screening to functional vaccine. Important to start with lectin or
antibody with functionality but not all CMPs selected will induce the
desired response. CMPs can be defined in a four-step process. (1) Lectins
that trigger apoptosis of tumor cells are defined. (2) Biopanning against a
random peptide display library identifies potential CMPs, which are
confirmed by carbohydrate-peptide inhibition assays. (3) The potential of the
CMPs to induce TACA-reactive antibodies is evaluated, as is (4) the ability of
CMP-induced antibodies to mediate apoptosis of tumor cells.
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Vaccine-induced anti-carbohydrate antibodies to both 106 and
107 (Table 2) reduced the outgrowth of micrometastases in the
4T1 spontaneous tumor model, significantly increasing survival
time of tumor-bearing animals. This finding parallels suggestions
that carbohydrate-reactive IgM with cytotoxic activity may have
merit in the adjuvant setting if the right carbohydrate-associated
targets are identified (81, 82). Interestingly, while both CMPs 106
and 107 are reactive with lectins only 107 induced responses that
were directly cytotoxic to tumor cells. Both CMPS induced anti-
bodies that mediated CDC,however,only CMP 107 induced serum
IgM antibodies in mice that mediated the apoptosis of murine 4T1
and human MCF7 cell lines in vitro, paralleling the apoptotic activ-
ity of the lectins (80). This finding again highlights that selection
of CMPs based upon antigenic mimicry does not automatically
translate into inducing antibodies with a desired functionality.
Fundamental feature of these CMPs was their hydrophobic
nature being built on motifs containing aromatic residues. Early
on, peptides that mimic carbohydrate antigens were identified
by analysis of reactivity of random peptide libraries on phage
with the lectin Concanavalin A (ConA) (16, 17). These early
peptides contain aromatic side chains, representing a generalized
Trp/Tyr/X/Tyr (were X is a number of different residues) motif.
Subsequent to these seminal studies other aromatic peptides dis-
playing similarities to ConA-reactive ones were described (18, 83).
Aromatic residues, hydrophobic, and hydrogen bonding amino
acids seem favored but with the possibility that the W/YXY motif
functionally mimic elements of Core 1 and 2 structures shared
among otherwise dissimilar carbohydrate structures (Figure 2).
Consequently, this motif type has been observed in peptides iso-
lated by a number of anti-carbohydrate antibodies and lectins
and might represent low-complexity surfaces (Figure 1) perhaps
because of the bias in the amino acid composition of the mimetics.
Such biased sequences do not necessarily converge on a canonical
set of patterns although some motifs stand out. It is important to
note how those peptides reactive with ConA were identified based
upon a conception of antigen mimicry, as the work of Westerink
et al. (18) were based upon immunological studies starting with
an anti-Id that displayed immunological functionality.
Structure-based reverse engineering to discover peptide mimics
The caveats associated with screening libraries with either lectins
or with antibodies often lead to identifying mimics that fail to
mimic critical contacts that the carbohydrate makes with the
protein, and there is a possibility that such peptides may bind
to alternative sites on protein to the carbohydrate-binding site,
making optimization of a true structural mimic from such a pep-
tide impossible (84). The structural approaches to define the basis
of mimicry have been previously discussed (13, 14). As mentioned
above high-affinity peptides per se may not necessarily mimic
critical contacts required for the function. In addition, the judi-
cious choice of peptides for testing antibody responses against
should be based on the peptide interaction with both the heavy
and light chain in order to induce antibodies with similar anti-
gen specific properties (28); as the combination of heavy and light
chains will influence specificity. Thus, both the variable and the
constant region of the antibodies induced by a peptide mimic or
mimotope must be considered when assessing the success of any
immunization.
To overcome the limitation of high-affinity peptides’ lack
of immunological mimicry, we adopted a “reverse engineering
approach” sometime ago, which places emphasis on the maintain-
ing critical contacts between carbohydrates and its protein partner
(28, 29). This method is similar to fragment-based drug discov-
ery (28). We have previously reviewed the structural concepts and
approaches used in vaccine design applications that illustrate the
value and limitations of using chemical (peptide libraries which
are mimics of a ligand) and immunological information to define
novel peptide immunogens that function as mimotopes to gen-
erate immune responses targeting TACA (85) and glycans on the
human immunodeficiency virus (86). In this context, we showed
that concepts associated with pharmacophore design (now consid-
ered reverse engineering) could be used to define CMPs applied to
vaccine design (21, 28). We demonstrated a structure-assisted vac-
cine design approach, whereby small molecules, defined in crystal-
lographic databases, could be used in principle to define peptide
mimetics emulating the three-dimensional interaction scheme of
a native carbohydrate antigen (21, 28). More importantly, it was
shown that virtual screening led to motifs being observed experi-
mentally and that they could display binding energetics similar to
the nominal carbohydrate antigen (28).
We have also shown that by using this approach, an immuno-
genic peptide (911 Table 2) can be designed de novo using ConA
as a template inducing antibodies with the same functionality as
ConA in neutralizing HIV isolates (21). In addition, we showed
that peptides could adopt structures that are similar to carbohy-
drate conformations that include extended beta strand type and
helical structures (21). Using reactivity patterns of glycan bind-
ing to ConA coupled with structural design concepts we identified
a peptide (referred to as 911) (Table 2) that when rendered as
a multiple antigenic peptide (MAP) was reactive with ConA at
Table 2 | Selected CMPs that we have studied.
Peptide Sequence Lectin Functionality
911 YRYRYGRYRSGSYRYRYGRYRSGS Con A Neutralizes HIV Lab isolates
912 RYRYGRYRSGS Con A
106 GGIYWRYDIYWRYDIYWRYD GS-1, WGA Mediates CDC
107 GGIYYRYDIYYRYDIYYRYD GS-1, WGA CDC, Apoptosis
P10 GVVWRYTAPVHLGDG GS-1, WGA Tumor growth inhibition
P10s WRYTAPVHLGDG GS-1, WGA Tumor growth inhibition in mice, apoptosis in humans
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lower concentrations than those required for reaction of some
native oligosaccharide ligands of ConA (21). The 911-MAP dis-
played competitive inhibition with carbohydrate ligands of ConA,
indicating that it binds at an overlapping carbohydrate-binding
site on ConA. Isothermal Calorimetric analyses and immunopre-
cipitation experiments suggest that a shorter monovalent puta-
tive peptide 912 (Table 2) exhibited a weak affinity compara-
ble to that of MeαMan (21). The 911-MAP exhibited a higher
association constant and free energy of association with ConA
compared with that found upon binding of the putative 912
peptide and the Ka and ∆G values of 911-MAP are compara-
ble to those of ConA-reactive trimannoside and pentasaccharide
(21). Most importantly, the 911-MAP induce antibodies in mice
that are capable of neutralizing HIV-1 III-B as assessed by p24
ELISA (21). This is work perhaps for the first time demonstrated
that design-principles associated with CMPs could be useful to
induce functional antibodies. Similar approaches have since been
applied to investigate peptide recognition by anti-alpha-Gal anti-
bodies (87) and in developing CMPs of gangliosides (88). As in
our studies, it was found that peptides could interact with the
same residues as those involved in carbohydrate recognition. In
this context, CMPs are envisioned to be further enhanced as
either inhibitors much like that in mainstream pharmacophore
development or as in our case to develop vaccines targeting
glycans.
To further emphasize the design principles to enhance the
fidelity of mimicry, we tested the hypothesis that improving
the hydrogen bond pattern through amino acid substitutions
in a CMP, to be coincident with that for the carbohydrate lig-
and, will enhance the ability of CMPs to elicit anti-TACA anti-
bodies with high titers and association constants (29). Based
on anti-Id/Id crystal structures, highly directional bonds rep-
resent an important set of interactions to establish a basis for
mimicry because they mainly confer the specificity in bind-
ing of the peptide and the carbohydrate antigen. In this exer-
cise, we developed the CMP P10s (Table 2) (29). This CMP
was identified from a random peptide library screen using the
anti-GD2/GD3 antibody ME36.1 (89). P10 was shown to gen-
erate immune responses in mice that inhibited tumor growth
in vivo (90).
In the development of P10s, we made use of the crystal struc-
ture of the anti-ganglioside antibody ME36.1 (29). Briefly, the
crystal structure of ME36.1 was analyzed in the context of com-
paring GD2 binding and CMP binding using a molecular docking
approach (29). Based on the hydrogen bonds interaction between
GD2 and CDRs of ME36.1, P10s was designed. Conformational
and docking calculations suggested that P10s would form an
increased number of hydrogen bonds with ME36.1 that are in
common with the GD2 hydrogen bond interaction pattern with
ME36.1 [see Table 1 in Ref. (29)]. This increased level of mimicry
would suggest that the immune response to GD2 upon immuniza-
tion with P10s would be better. We observed that P10s did indeed
induce higher titer antibodies to the target antigen and antigen
expressing tumor cells than the parent CMP, P10. These stud-
ies suggest that for carbohydrate mimics, pharmacophore based
design is superior over the conformational approach undertaken
for other peptide mimics.
PRECLINICAL ASSESSMENTS OF CMPs
Tumor-associated carbohydrate antigen are rather varied in their
expression profiles on tumor cells and on normal tissue. TACAs
are upregulated in many types of tumors, and therefore rep-
resent a potential vaccination target with widespread appli-
cation. Cancer vaccines functionally resemble the process of
autoimmune-mediated tissue damage (91).
Since tissue rejection is the goal of cancer immunotherapies,
broad-spectrum, pan-antigens like TACA are plausible effective
targets once the problem of their low immunogenicity is solved.
This is the hope of CMP and anti-idiotypic vaccine research.
The basis of TACA mediate tumor rejection is akin to
the observation that anti-Gal IgM and IgG mediate rejection
of xenograft expressing α-gal glycoconjugates with terminal
Galalpha1-3Galbeta1-4GlcNAc sequences (alpha-galactosyl epi-
topes, natural xenoreactive antigens) that are present on various
tissues in pigs and are recognized by human anti-alpha-galactosyl
(alpha-Gal) antibodies (92). The tissue-rejection mediated by
α-Gal-reactive antibodies demonstrates the feasibility of target-
ing TACAs for tumor therapy because tumor-induced antibody
responses resemble autoimmune responses (93).
The generation of tissue-rejection represents an important con-
ceptual approach to cancer immunotherapy. Alpha-galactosylated
xenoantigens (Galalpha1-3Galbeta1-4GlcNAcbeta1 and Galalpha1-
3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc) are often detected
with the alpha-Gal-reactive lectin GS-1. However, this lectin
exhibits a broad and variable specificity for carbohydrates ter-
minating in alpha-Gal (94). The blood group reactive lectin GS-I,
which recognizes alpha-galactosyl moieties is recognized as a sur-
rogate marker to identify tumor expressed antigens reactive with
anti-Gal antibodies and GS-I is of utility to interrogate terminal
α-GalNAc/Gal expression on human tissues (95). Some of these
antigens are also expressed on normal cells at low levels, potentially
creating a state of immune tolerance.
We have previously demonstrated that vaccination with the
CMPs 106 and 107 (Table 2) can induce antibody responses lead-
ing to cell-mediated cytotoxicity and apoptosis, respectively, in
murine models of cancer (80). In preclinical studies, we observe
that immunization in mice with these CMPs do not induce sig-
nificant immunopathology, organs including liver, kidney, heart,
lungs, intestines, stomach, lymph nodes, spleen, brain, spinal cord,
and eyes were examined in H&E stained sections. These organs
are reactive with GS-1 and the CMPs induce antibodies reactive
with GS-1 antigens (29, 64). No significant cellular infiltrates were
identified in any organ, including brain and spinal cord, from any
animal, and there was no evidence of necrosis or extensive apop-
tosis in these sections (29, 64). It is likely that the level or pattern of
expression of these molecules on the surface of tumor cells differs
significantly from that on normal cells mediated by antibody avid-
ity and the clustering of glycan epitopes (96). This difference in
expression may account for the relative specificity of immunologic
injury for tumor cells over normal cells.
Antibodies induced by CMPs are thought to have low affinities
for TACA that might compensate for the low-affinity of the car-
bohydrate cross-reactive antibodies, minimizing the destruction
of normal tissue. Such results demonstrate that repeated injec-
tions of CMPs do not necessarily lead to immune mediated injury
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and support the development of CMPs for clinical testing (29,
64). Bringing such vaccines to the treatment armamentarium may
significantly improve outcomes for patients.
CLINICAL ASPECTS OF MIMICRY
The potential benefits of inducing TACA-reactive antibodies in
patients with cancer are demonstrated by observations that patient
survival significantly correlates with ganglioside-reactive IgM lev-
els (97). The fact that survival rates of cancer patients are correlated
with low-titer, and presumably low-affinity, TACA-reactive anti-
bodies argues that more robust antibody responses may not be
necessary. Cross-reactions are important issues in vaccine the
development field. As self-antigens induce tolerance, vaccination
with non-self-antigens that molecularly mimic self-antigens may
avoid tolerance and lead to generation of anti-tumor immune
responses. In this context, little attention has been paid to the
fact that the tumor-associated antigen MUC1 might be a natural
CMP. In a series of studies from McKenzie’s group, it was noted
that anti-α-Gal antibodies reacted with MUC1 antigens and that
anti-MUC1 antibodies reacted with the α-Gal sugar (56). In mice,
MUC1 peptide immunization resulted in cellular responses with
reported little humoral response. In contrast, the MUC1 peptide
induced a strong antibody response in human immunization. It
was argued that pre-existing anti-Gal antibodies in human was the
basis for the differential response as the Gal-epitope is a natural
antigen in mice (56).
The mimicking of MUC1 with the Gal-epitope might have
important consequences. The natural cross-reactivity of anti-Gal
antibodies against MUC1 might lend to confusion making it dif-
ficult to ascertain the relative contributions of antibodies in bind-
ing to MUC1 upon MUC1 immunization; e.g., whether one can
dissect if anti-MUC1 antibodies are not anti-TF and whether anti-
MUC1 antibodies are not anti-Gal antibodies (98). On the other
hand, the cross-reactivity of anti-Gal antibodies with MUC1 might
lend to anti-MUC cellular immunity. Dendritic cells (DCs) play
an important role in the induction of T-cell responses. Fc gam-
maRs (FcγR), expressed on DCs, facilitate the uptake of complexed
antigen, resulting in efficient MHC class-I and MHC class-II Ag
presentation and DC maturation (99, 100). IgG-complexed MUC1
internalized through FcγR on DCs might be are efficiently pre-
sented to CTLs through the MHC class-I pathway as observed in
other systems (99, 100). However, these mechanisms might also
responsible for antibody-mediated enhancement in vivo as sug-
gested by the McKenzie work in humans and in animal models
where antigen-IgG and IgE complexes exacerbated Th2 cells rather
than Th1 cells (101). Therefore, mimicry of the Gal-epitope by
MUC1 might skew Th2 type responses to MUC1 vaccines, which is
contradictory to the present paradigm that stresses Th1 responses
as being beneficial to MUC1 and other tumor-associated antigens.
While CMPs of TACA have been described that include the
ganglioside GD2 (89, 95, 102–105), the ganglioside GD3 (106),
sialylated Lewis a/x (107), and LeY (89), none of these CMPs
have made it to the clinic except for our P10s. In contrast, sev-
eral anti-idiotypic antibodies that mimic different GD2 (108–
111), GD3 (112), and N-glycolyl (NGc) gangliosides (40) have
made it to clinical trials. The most advanced is the GD3 mim-
icking antibody Bec2, which has been tested in a Phase III trial
(112). Unfortunately, there was no improvement in survival or
progression-free survival in the vaccination arm with Bec2. Each
of these anti-idiotypes seems to have a different mechanism of
action against cancer cells but parallel mechanisms observed with
CMPs. In the case of the anti-idiotype that mimics NGc ganglio-
sides it generates a humoral response that triggers cell death but
differently than typical apoptosis (113). Patients that developed
IgG and/or IgM Abs against NeuGcGM3 showed longer median
survival times (114). Immunizations with the GD2/GD3 surro-
gates are less mechanism based. Bec2 induces antibody responses
in about 25% of subjects (115). Consequently, different strate-
gies using Bec2 have been considered including priming (38) and
in combination therapy with adjuvant (116). For GD2, the anti-
idiotypes induce GD2 reactive antibodies, which mediate ADCC
activity. This type of data suggests that the anti-idiotypes generally
generate IgG1 type antibodies are efficient at ADCC (108) while
IgG2, which are considered carbohydrate reactive is minimal at
mediating ADCC.
FUTURE DEVELOPMENT OF STRUCTURE-BASED VACCINES
Glycans or TACAs are important targets for cancer immunother-
apy as suggested by immune surveillance mechanisms. TACAs
display important biological effects in tumor biology and tumor
immunology. Most importantly, the recognition properties of
glycans by immune effector cells have suggested translational
strategies in immune therapy. In this review, we elaborated on
achievements that facilitate rational vaccine design using CMPs.
In nature, immunogenic parts of pathogens and cancer cells that
provide antigens for B-cell receptors and antigenic peptides that
are presentable by MHC molecules to TCR have to be identified.
There is much to learn from the B/TCR that see carbohydrates as
antigens and then as immunogens. Carbohydrates define recogni-
tion patterns, which activate the innate immune system to induce
an appropriate adaptive immune response. Regular considerations
in using CMPs that are selected upon binding to these receptors
have not been pursued in the clinic with much fervor. This is partly
due to the perception of utility and the idea that we need “specific”
responses to singular carbohydrate antigens. More thought needs
to be directed toward rational design approaches, which we have
shown can be successfully implemented and not indiscriminate
studies of co-crystallization or NMR studies with CMPs derived
from random phage screening that are selected biased toward
high-affinity binders (13–15).
While there are no universally accepted strategies and tools
to rationally design vaccines to elicit antibody responses, vaccines
should include B-cell receptor epitopes, but these might be more of
a clustered type as we have shown using MAP platforms. Nanopar-
ticle concepts could play a role here if they can be manufactured
under GMP clinical grade. MHC Class-I/II molecules process Gly-
copeptides and so it is thought that these could be incorporated as
well. The choice of carbohydrate might also impact on inducing
Th1 or Th2 responses. We have shown that naked peptides can do
the same however (63, 77). These glycopeptides or naked peptides
should display sequences that allow T-cell epitope formation in a
complex with MHC molecules but with the realization that there
are hundreds of alleles that are differentially combined between
individuals. Choosing immunogenic peptides presented by MHC
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faces the challenge of not only predicting sequences appropriate
for complex with a particular MHC allele, but also finding peptides
that can reliably build epitopes in the diverse genetic background
within a human population.
The diversity of regulatory mechanisms involving glycans
expands the range of possible effects of TACA targeting
immunotherapeutic approaches (117). Anti-TACA antibodies,
thus, may be involved in more than direct tumor cytotoxicity even
though this mechanism is exciting. Although, the exact mech-
anism may represent a cascade of steps that are still to be estab-
lished, TACA targeting has the potential to yield anti-tumor effects
mediated by Natural Killer cells, which has not been thoroughly
investigated in humans even though there is some evidence of
therapeutic benefit (118, 119) or through neutralization of tumor
immunosuppressive factors in the form of soluble gangliosides
(120–122). Future work should clarify the points of involvement of
antibody/carbohydrate interactions in modulating tumor growth
and facilitating innate surveillance mechanisms.
The number of manuscripts published on CMPs has certainly
diminished in recent years. The promise of CMPs ‘to be func-
tional in animal models of bacterial infection has been impressive
starting with our own (18), yet no CMP for bacterial antigens has
made it to the clinic. The same is said for anti-idiotypes of bacte-
rial carbohydrate antigens. In the cancer area only our P10s CMP
has made it to the clinic. Perhaps the problem with diminished
work on CMPs is more about the perception of mimicry rather
than outcomes. The same has been suggested for anti-idiotypes
(34). In mouse models, CMPs are functionally relevant much like
anti-idiotypes. But clinically, all vaccine types, mimic or not, dis-
play less than optimal activity. The focus in immunotherapy has
therefore been centered on checkpoints that mediate the immune
response. Nevertheless, the promise of CMPs and other surrogates
of carbohydrates is to better understand the structural implica-
tions of the antibody-mediated interactions that has the potential
for innovation in terms of rational design of reagents with bio-
logical, chemical, and pharmaceutical applications that underlies
concepts of reverse immunology which is highlighted herein.
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